This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
HYDERABAD: Natco Pharma Ltd has launched a generic version of Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination in Nepal.
It will market the product under the VELPANAT brand name and priced at an MRP of Rs.25,000 equivalent for a bottle of 28 tablets in Nepal. [This is $492 CDN a bottle]
The launch is under a non-exclusive licensing agreement that Natco has with Gilead Sciences Inc. to manufacture and sell generic versions of the latter’s chronic hepatitis C medicines in 101 developing countries. The fixed dose combination is sold by Gilead Sciences Inc. under the Epclusa brand name. Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection, a Natco Pharma release on Monday said.